Company intelligence / Profile preview

Zephyrm Biotechnologies

Beijing, Beijing, Chinazephyrm.com ↗

Ownership: Private
Development stage: Phase 2

Overview

ZH901 has shown a ~78% response rate in acute GvHD patients with no serious adverse effects reported among about a hundred treated patients. Early studies also show improvements in pulmonary fibrosis post-COVID and promising results in meniscus injuries. Other programs are at earlier stages but have demonstrated initial efficacy signals, such as improved motor function in Parkinson's models

Therapeutic areas: PulmonologyImmunologyRheumatologyOphthalmologyNeurology
Modalities: Pluripotent stem cell-derived therapies (PSC-derived cell therapy)Stem cell therapy
Industry: Biotech

Drug pipeline

1 asset

CAStem

Phase 2

Indications: Acute graft-versus-host disease, Acute exacerbation of interstitial lung disease, Acute respiratory distress syndrome, Meniscal injury

Partnerships

Chinese Academy of SciencesBeijing Institute for Stem Cell and Regeneration

Beyond the preview

Go deeper on Zephyrm Biotechnologies.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Zephyrm Biotechnologies.

Explore the full profile